Security Snapshot

Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value (TBPH) Institutional Ownership

CUSIP: G8807B106

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

167

Shares (Excl. Options)

49,596,818

Price

$18.71

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Ordinary Share $0.00001 Par Value
Symbol
TBPH on Nasdaq
Shares outstanding
51,428,000
Price per share
$16.60
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
49,596,818
Total reported value
$927,239,223
% of total 13F portfolios
0%
Share change
+1,071,921
Value change
+$22,675,435
Number of holders
167
Price from insider filings
$16.60
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • TBPH - Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value is tracked under CUSIP G8807B106.
  • 167 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 167 to 24 between Q4 2025 and Q1 2026.
  • Reported value moved from $927,239,223 to $13,499,732.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 167 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP G8807B106?
CUSIP G8807B106 identifies TBPH - Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value (TBPH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Weiss Asset Management LP 14% $149,066,629 7,457,060 Weiss Asset Management LP 23 Mar 2026
Newtyn Management, LLC 8.5% -12% $87,419,000 -$9,299,003 4,300,000 -9.6% Newtyn Management, LLC 31 Dec 2025
BlackRock, Inc. 6.5% $31,548,036 3,235,696 BlackRock, Inc. 31 Mar 2025

As of 31 Dec 2025, 167 institutional investors reported holding 49,596,818 shares of Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value (TBPH). This represents 96% of the company’s total 51,428,000 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value (TBPH) together control 83% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Madison Avenue Partners, LP 18% 9,511,150 0% 7.6% $177,953,617
Weiss Asset Management LP 14% 7,457,060 0% 2.1% $139,521,593
Newtyn Management, LLC 8.4% 4,300,000 -13% 8.5% $80,453,000
BlackRock, Inc. 7.9% 4,050,525 -0.45% 0% $75,785,323
Irenic Capital Management LP 5.4% 2,760,948 0% 6.8% $51,657,337
VANGUARD GROUP INC 4.6% 2,367,353 +7% 0% $44,293,175
D. E. Shaw & Co., Inc. 2.4% 1,259,941 +4.2% 0.02% $23,573,496
ACADIAN ASSET MANAGEMENT LLC 2.3% 1,165,959 +7% 0.04% $21,806,000
STATE STREET CORP 2.1% 1,101,892 +4.4% 0% $20,616,399
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.9% 963,257 +33% 0.01% $18,022,538
GEODE CAPITAL MANAGEMENT, LLC 1.8% 938,724 +4.5% 0% $17,566,969
DIMENSIONAL FUND ADVISORS LP 1.7% 858,957 +12% 0% $16,071,946
MORGAN STANLEY 1.6% 803,119 +34% 0% $15,026,357
Oasis Management Co Ltd. 1.4% 727,161 -35% 1.8% $13,605,182
UBS Group AG 1.1% 570,425 +11% 0% $10,672,651
TWO SIGMA INVESTMENTS, LP 1% 537,341 +132% 0.01% $10,053,650
Qube Research & Technologies Ltd 0.92% 473,498 +124% 0.01% $8,859,148
MARSHALL WACE, LLP 0.81% 418,629 +17% 0.01% $7,832,548
JPMORGAN CHASE & CO 0.81% 416,408 +95% 0% $7,790,992
Assenagon Asset Management S.A. 0.79% 404,144 -2.5% 0.01% $7,561,534
JANUS HENDERSON GROUP PLC 0.78% 400,496 +215% 0% $7,493,280
TWO SIGMA ADVISERS, LP 0.74% 379,500 +89% 0.01% $7,100,445
TANG CAPITAL MANAGEMENT LLC 0.68% 351,252 +33% 0.32% $6,571,925
Pacer Advisors, Inc. 0.66% 338,958 0.02% $6,341,904
NORTHERN TRUST CORP 0.64% 329,927 -3.3% 0% $6,172,934

Institutional Holders of Theravance Biopharma, Inc. - Ordinary Share $0.00001 Par Value (TBPH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 832,142 $13,499,732 -$536,240 $16.23 24
2025 Q4 49,596,818 $927,239,223 +$22,675,435 $18.71 167
2025 Q3 48,375,344 $706,279,654 +$36,991,609 $14.60 159
2025 Q2 46,436,015 $512,193,131 +$17,041,767 $11.03 134
2025 Q1 44,895,013 $400,910,124 +$805,783 $8.93 130
2024 Q4 44,887,720 $422,397,233 -$6,899,094 $9.41 128
2024 Q3 45,764,660 $368,891,703 -$13,728,533 $8.06 118
2024 Q2 47,101,751 $399,477,630 -$8,156,185 $8.48 129
2024 Q1 47,958,440 $430,313,409 -$10,017,643 $8.97 119
2023 Q4 48,815,898 $548,690,907 -$21,251,604 $11.24 116
2023 Q3 50,811,645 $438,505,371 -$20,825,244 $8.63 113
2023 Q2 52,784,275 $546,345,758 -$76,354,796 $10.35 117
2023 Q1 60,151,070 $652,600,279 -$20,647,357 $10.85 112
2022 Q4 62,093,388 $696,433,955 -$41,903,451 $11.22 118
2022 Q3 64,074,481 $649,741,089 +$1,849,322 $10.14 114
2022 Q2 64,209,180 $581,714,921 +$11,702,533 $9.06 106
2022 Q1 62,986,284 $602,166,380 +$31,622,746 $9.56 114
2021 Q4 59,337,727 $655,471,603 -$7,845,717 $11.05 109
2021 Q3 60,653,808 $448,777,384 -$37,107,153 $7.40 111
2021 Q2 60,758,215 $882,854,201 +$106,504,226 $14.52 101
2021 Q1 53,537,579 $1,092,709,410 +$7,301,237 $20.41 104
2020 Q4 53,239,274 $946,045,510 +$17,733,590 $17.77 103
2020 Q3 52,459,569 $775,625,748 -$4,497,125 $14.78 113
2020 Q2 52,961,450 $1,111,646,885 -$95,003,651 $20.99 121
2020 Q1 56,904,286 $1,315,179,943 +$267,872,903 $23.11 102
2019 Q4 44,821,941 $1,159,982,320 -$103,049,474 $25.89 103
2019 Q3 46,191,630 $899,811,276 -$42,270,083 $19.48 87
2019 Q2 48,624,391 $794,038,148 +$6,064,175 $16.33 94
2019 Q1 48,467,789 $1,098,829,213 +$14,666,557 $22.67 98
2018 Q4 47,693,431 $1,220,447,234 -$168,216 $25.59 92
2018 Q3 47,402,456 $1,548,591,468 +$9,259,415 $32.67 90
2018 Q2 47,820,954 $1,084,574,647 +$2,240,117 $22.68 83
2018 Q1 47,702,533 $1,156,766,841 +$19,411,519 $24.25 85
2017 Q4 46,927,458 $1,308,786,945 -$13,545,795 $27.89 79
2017 Q3 47,312,839 $1,619,998,372 +$33,457,548 $34.24 80
2017 Q2 46,303,381 $1,844,748,924 +$47,996,533 $39.84 91
2017 Q1 45,113,403 $1,660,949,113 +$168,197,871 $36.82 90
2016 Q4 43,817,541 $1,396,888,696 +$262,074,543 $31.88 96
2016 Q3 35,300,039 $1,277,832,411 +$76,633,705 $36.24 98
2016 Q2 33,917,613 $769,608,364 +$131,840,765 $22.69 94
2016 Q1 28,150,667 $529,049,830 +$42,674,071 $18.80 77
2015 Q4 25,928,974 $424,968,625 +$85,947,257 $16.39 79
2015 Q3 20,539,324 $225,719,337 -$24,553,140 $10.99 78
2015 Q2 22,422,337 $291,927,279 +$16,321,496 $13.02 84
2015 Q1 20,888,616 $362,467,742 +$7,467,773 $17.35 84
2014 Q4 20,412,218 $304,588,647 -$33,281,851 $14.92 86
2014 Q3 21,271,423 $490,440,514 +$17,057,826 $23.05 86
2014 Q2 20,300,819 $647,804,482 +$647,740,494 $31.88 89
2014 Q1 842 $14,609 $17.35 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .